Tudor Investment Corp ET AL Buys 150,597 Shares of Bausch + Lomb Co. (NYSE:BLCO)

Tudor Investment Corp ET AL boosted its stake in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 133.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 263,299 shares of the company's stock after acquiring an additional 150,597 shares during the period. Tudor Investment Corp ET AL owned 0.07% of Bausch + Lomb worth $4,755,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BLCO. Blue Trust Inc. boosted its holdings in shares of Bausch + Lomb by 68.3% in the fourth quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock worth $48,000 after buying an additional 1,004 shares during the last quarter. FNY Investment Advisers LLC bought a new position in Bausch + Lomb in the 4th quarter worth $72,000. Commonwealth Equity Services LLC purchased a new stake in shares of Bausch + Lomb during the fourth quarter worth about $181,000. Alpine Global Management LLC purchased a new position in Bausch + Lomb in the 4th quarter worth approximately $181,000. Finally, Covestor Ltd purchased a new stake in Bausch + Lomb during the 4th quarter valued at approximately $188,000. 11.07% of the stock is owned by institutional investors.

Bausch + Lomb Stock Up 1.5 %

Shares of NYSE:BLCO traded up $0.17 during midday trading on Wednesday, hitting $11.07. 165,677 shares of the stock were exchanged, compared to its average volume of 649,228. The business's fifty day simple moving average is $13.72 and its two-hundred day simple moving average is $16.75. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.60. Bausch + Lomb Co. has a 52-week low of $10.45 and a 52-week high of $21.69. The company has a market capitalization of $3.91 billion, a PE ratio of -12.15, a P/E/G ratio of 0.85 and a beta of 0.58.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.10). Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. The business had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same quarter last year, the firm earned $0.07 earnings per share. Bausch + Lomb's revenue was up 3.5% compared to the same quarter last year. As a group, research analysts predict that Bausch + Lomb Co. will post 0.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Citigroup cut their target price on shares of Bausch + Lomb from $14.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday, May 1st. Morgan Stanley decreased their price objective on Bausch + Lomb from $18.00 to $12.00 and set an "equal weight" rating for the company in a report on Tuesday. Evercore ISI dropped their price target on Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating on the stock in a research note on Thursday, May 1st. Needham & Company LLC reiterated a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, April 24th. Finally, Stifel Nicolaus reduced their target price on Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating for the company in a report on Thursday, April 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Bausch + Lomb currently has a consensus rating of "Hold" and a consensus price target of $15.50.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.